Mechanistic Evaluation of Therapeutic Targets derived from Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33 Clinical Trial Not Allowed)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Oct 23, 2025
- Closes
- Oct 28, 2027 (in 392 days)
Similar opportunities open now
- Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Oct 2027
- Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Oct 2027
Classification and identifiers
- Solicitation number
- RFA-MH-27-125
- Assistance listing (CFDA)
- 93.853
Amount
Amount not published by the funder
Who can apply
Public colleges and universities, State government agencies, and Small businesses can all apply here. Check the eligibility details below to see if your organization fits.
About this opportunity
The National Institute of Mental Health intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research to identify modifiable targets and mechanisms to alleviate clinically relevant central nervous system (CNS) complications in people with HIV. This NOFO supports research that leverages patient derived data and innovative model platforms to identify and validate novel therapeutic targets underlying CNS complications. Building on advances in systems biology, this initiative seeks to identify modifiable mechanisms contributing to CNS dysfunction through clinical studies or pre-clinical model systems. The ultimate goal is to accelerate the development of effective, mechanism-based interventions that address the multifactorial and heterogeneous nature of CNS com...